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Chapter 6 
Determination of an Immunocontraceptive 
Peptide in a Wildlife Vaccine Formulation 
David A. Goldade,* Jeffrey M. Kemp,I Jeanette R. O'Hare, and 
Lowell A. Miller 
USDA/APHIS/WS/National Wildlife Research Center, 4101 LaPorte Avenue, 
Fort Collins, Colorado 80521 
1Present address: Colorado Serum Company, 4950 York Street, 
Denver, Colorado 80216 
*E-mail: David.A.Goldade@aphis.usda.gov 
Wildlife populations continue to grow despite the use 
of traditional management techniques. GonaCon™ 
Immunocontraceptive Vaccine is a vaccine used to reduce 
reproduction in mammalian species, including white-tailed deer 
(Odocoileus virginianus). The vaccine consists of synthetic 
gonadotropin releasing hormone (GnRH) conjugated to a 
mollusk hemocyanin (Concholepas concholepas) prepared 
as an emulsion with mineral oil to promote a prolonged 
immune response. Development of an analytical method for 
determination of the active ingredient in the vaccine formulation 
was complicated by the emulsion and conjugation of GnRH 
to the carrier protein. Breaking the emulsion was achieved 
chemically by addition of diethyl ether. The aqueous portion 
containing the GnRH conjugate was cleaved enzymatically 
with a protease (clostripain) at the arginine-proline site of 
its peptide sequence. Hydrolysis produced a diagnostic eight 
amino acid peptide fragment which was unique to GnRH and 
easily quantified by LC/MS/MS. Typical recoveries of fortified 
samples at the target concentration exceeded 90%. 
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Introduction 
Wildlife populations, in particular wild deer populations have been steadily 
increasing since the early J 900 's when population estimations placed the number 
of wild deer in the US at approximately 500,000 (I). Restocking and conservation 
efforts were undertaken to replenish the populations. These efforts have been 
extremely successful to the point that a serious overpopulation problem now exists, 
particularly in urban and suburban areas (2). Current population estimates are 
in the neighborhood of 20 million individuals. Population densities can reach as 
much as 40 to I 00 individuals per square mile in some urban and suburban areas 
(3). These high population densities can lead to severe wildlife management issues 
including increased deer-vehicle collisions ( 4), damage to ornamental plants or 
crops (5), degradation of habitat quality for other wildlife due to overgrazing (6, 
7), and possible disease transmission to other wild or domestic animals as well as 
human populations (8, 9). 
Management techniques typically employed to minimize deer-human 
conflicts in rural settings include culling, the use of scare devices, or exclusion 
fences. Firing high powered rifles in urban areas has very little support from 
members of the public who live in the areas where control is needed (JO). 
Scare devices are either wholly ineffective or are only effective for a short time 
before the animals become habituated to them (11, 12). Exclusion fences are 
not practical in many settings, can be cost prohibitive, and must be extremely 
tall in order to keep highly agile deer from jumping over them (13). Ecosystem 
controls such as the introduction of predators is not feasible in urban settings 
(14). A long-term management solution must include new tools in an integrated 
approach. A technique such as immunocontraception used to limit reproduction 
of local populations is such a tool. 
GonaCon™ Immunocontraceptive Vaccine (hereafter GonaCon™) is an 
immunocontraceptive vaccine registered with the Environmental Protection 
Agency (EPA) under the Federal Insecticide, Fungicide, and Rodenticide Act 
(FIFRA) for use with female white-tailed deer 1 year of age or older (15). In 
addition to registration with EPA, use of this product requires registration within 
each state and approval by the State natural resource agency responsible for 
managing wildlife. Currently, it is only registered for use in New Jersey and 
Maryland. 
Oona Con TM consists of a synthetic gonadotropin releasing hormone peptide 
(GnRH) conjugated to a mollusk hemocyanin (blue protein or BP). The conjugated 
protein is mixed with mineral oil and a surfactant to produce an emulsion 
(16, 17). The final vaccine emulsion is delivered to the target animals via a 1 
mL intra-muscular injection (17, 18). The conjugated protein stimulates the 
production of antibodies that bind to endogenous GnRH. By binding to GnRH, 
the antibodies reduce GnRH's ability to stimulate the production of sex hormones 
such as estrogen, progesterone, and testosterone. As a result, all sexual activity is 
decreased and the animals remain in a nonreproductive state as long as a sufficient 
level of antibody activity is present. 
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In order to support the continued registration of GonaCon™, an Enforcement 
Analytical Method is required by the EPA. The method needed to be accurate and 
reliable. It also needed to be sensitive enough to detect small differences in the 
active ingredient content of the final vaccine. 
Methods 
Reagents 
Formic acid (LC-MS Grade), DL-dithiothreitol, 2,2,2-trifluoroethanol, and 
calcium chloride dihydrate were all obtained from Sigma-Aldrich (St. Louis, 
~ '° MO). Acetonitrile (Optima Grade), diethyl ether (anhydrous), sodium phosphate 
·o ~ 1l monobasic, and potassium hydroxide were obtained from Fisher Scientific 
. (.) 
..§ ~ (Pittsburgh, PA). Clostripain (87 units/mg dry weight; Endoproteinase-Arg-C) 
$:::::: was purchased from Worthington Biochemical (Lakewood, NJ). Gonadotropin 
B-rA 
.:::: 0 releasing hormone (GnRH; [pE]HW SYG LRP GGC-CONH2; 95.42% 
...., ~ pure) was synthesized by GL Biochem (Shanghai, China). Peptide-1 
c;.e 
N - ([Pyr]HWSYGLR-Acid; 97.39% pure) was synthesized by Pi Proteomics 
.N 
N ~ (Huntsville, AL). 
t;.;o ~-:-'. The mobile phase consisted of a mixture of 0.1% formic acid in deionized 
< :.§ water and acetonitrile. Deionized water was purified using an E-Pure water c _ 
~ ~ purification system (Barnstead, Dubuque, IA). The sample extraction solution was 
-o ~ ~· prepared by combining approximately 0.36 g of sodium phosphate monobasic 
0 :;;; and 40 mg of DL-dithiothreitol in 60 mL deionized water. The pH was adjusted 
Cj ~ to approximately 7.6 with a solution of 1 M potassium hydroxide. To this solution 
t§ ~ 5 mL of 2,2,2-trifluoroethanol was added before diluting to a final volume of 
Ii.. ::0 o ~ I 00-mL with deionized water. The enzyme activation solution was prepared 
~ ~ by combining approximately 15 mg of calcium chloride dihydrate and 40 mg 
::i -~ of DL-dithiothreitol. The solution was diluted to 100 mL with deionized water ;;...O 
~ .§ before use. 
i .~ A concentrated stock solution of GnRH and Peptide- I was prepared by 
~ =§ weighing 1.000 mg of each and dissolving them in 5.00 mL of deionized water. 
~ 11.. 8 Working standards, ranging in concentration from 10 ng/mL to 2 µg/mL, were 
prepared by dilution of stock solutions with a solution of 9: 1 0.1 % formic acid 
in deionized water:O. l % formic acid in acetonitrile. All standard solutions were 
stored at 5°C prior to use. A representative chromatogram is shown in Figure 1. 
Sample Analysis 
Breaking the Emulsion 
GonaCon™ vaccine aliquots (0.5 g) were placed in 15-mL glass centrifuge 
tubes. One milliliter of extraction solution was added to each sample. The 
sample was vortexed to suspend the vaccine material followed by centrifugation 
at approximately 5,000 g for 2 minutes. Diethyl ether was used to break the 
emulsion and separate the mixture into an organic and aqueous layer. This was 
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accomplished by adding three successive 5 mL aliquots of ether followed by a 
vortexing and centrifugation step to separate the organic and aqueous layers. 
The upper, organic layer was discarded and the aqueous layer was transferred 
to a 5-mL volumetric flask and diluted to produce a solution containing 5% 
trifluoroethanol in phosphate buffer . 
..:10 4 .,.ESI T1C MRM CID@ .. (""-> 0 ) Sys1em_Suil·r009.d 
1 
I Peptide-1 I 
3.800 
~.015 
x10 4 +ESI MAM Frag,.122.0V CID@20.0 (515.4-> 249.0) Syal9fl\..Suh-r009.d 
I GnRH I 
I Peptide-1 I 
3.802 
x10 4 +ESI MRM Frag=132.0V CID@32.0 (672.0-> 249. 1) Sy&tem_Suh-f009,d 
1 
4.014 
0.5 1.5 25 3.5 4.5 6 5.5 
Counra vs. Acquisition Time (min) 
6.5 7.5 8.5 
Figure 1. Chromatogram of a 500 nglml standard solution. 
Enzymatic Cleavage 
9.5 
A solution of activated clostripain was prepared by weighing approximately 
0.25 mg of clostripain into a 1.5-mL microcentrifuge tube and adding I mL of 
enzyme activation solution. A 50 µL aliquot of sample extract was removed and 
reacted with 50 µL of the clostripain solution in I mL of extraction solution to 
produce the peptide fragment. The enzyme reaction was conducted in a water bath 
held at approximately 25°C for two hours. Following completion of the reaction, 
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1 mL of a solution of 8:2 0.1 % formic acid in deionized water:0.1 % formic acid 
in acetonitrile was added and the sample was centrifuged to remove any heavy 
protein fragments. This clarified solution was injected into the LC/MS/MS and the 
concentration of the diagnostic peptide fragment was quantified. Each sample was 
analyzed for both total GnRH content and free (or unconjugated) GnRH content 
by preparing a second sample which contained all of the components except the 
clostripain. 
High-Performance Liquid Chromatography Tandem Mass Spectrometry 
The analytical system consisted of an Agilent 1200 liquid chromatograph 
coupled to an Agilent 641 OA-2K triple quadrapole mass spectrometer (Palo 
Alto, CA). Instrumental parameters are listed in Table 1. The mass spectrometer 
was operated in the multiple reaction monitoring (MRM) mode (Table II). The 
precursor ion for both GnRH and Peptide-I had a z value of 2. Therefore, the base 
peak for each was found at half the mass of the molecule. Following collision in 
the mass spectrometer, the product ions were found to have z values of l. This led 
to a situation in which the product ions had larger m/z than the precursor ions for 
the quantification transition for each analyte. The proposed fragment ions can be 
seen in Figures 2 and 3. The m/z of the precursor ions are given in the lower left 
comer of each figure. The lines indicate the site of fragmentation for each product 
ion as well as the corresponding m/z value for each. The calibration standards ( 10 
- 2,000 ng/mL) were injected in triplicate and subjected to a weighted quadratic 
regression. Quantification was accomplished by comparing analyte responses to 
the external standard calibration curve. 
HN ~NH2 
Oy~~yO(~H 
HS /h~w? H OH 
site of enzymatic cleavage r O ~ H h ? 
HO H 
m/z = 249 
(!o 
NH_( .. 
0 H 
~ ) 
m/z = 908 
m/z = 672 
Figure 2. Mass fragmentation of GnRH 
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mlz = 249 
m/z = 515 m/z = 595 
Figure 3. Mass fragmentation of Peptide-I. 
Quality Control Samples and Fortification of Controls 
A sham vaccine was prepared in the same manner as the GonaCon vaccine. 
This sham contained all of the components except GnRH and was prepared using 
the same protocols as the vaccine samples. The sham was fortified with a solution 
of GnRH in deionized water to produce fortification levels 50% above and below 
the target level for the vaccine (300 µg/mL). The quality control samples were 
extracted and analyzed using the same procedure described above. 
Results and Discussion 
Enzymatic Cleavage 
The GonaCon™ vaccine is manufactured by conjugating the synthetic 
GnRH peptide to a mollusk hemocyanin protein via a sulfo-SMCC linker. Direct 
measurement of the fully conjugated protein was not possible due to the mass 
of the BP (approx.. 8 mDa). Attempts were made to analyze the final vaccine 
through the use of near infrared transflectance. This approach proved to be 
unfeasible possibly due to the high background created by the BP. The GnRH 
could easily be measured in solutions via HPLC, but not when linked to BP. 
The use of this linker produced a very stable and rugged link between the two 
154 
In Evaluating Veterinary Pharmaceutical Behavior in the Environment; Cobb, G., et al.; 
ACS Symposium Series; American Chemical Society: Washington, DC, 2013. 
components of the vaccine. However, this linkage is irreversible. Various 
solvents, acids, bases, and buffer treatments were investigated in an attempt to 
break this linkage. All efforts were unsuccessful. Clostripain is a proteinase 
isolated from Clostridium histolyticum which is highly specific for the carboxyl 
peptide bond of arginine and cleaves the GnRH at the cysteine residue in the 
conjugate (Figure 2) (19). This produces a smaller fragment of GnRH which has 
been called Peptide-I. Peptide- I results from one GnRH molecule in a directly 
proportional relationship. Treatment of the sham vaccine with clostripain did not 
produce any measurable Peptide-I. By use of this enzyme, direct measurement of 
GnRH content in GonaCon vaccine was accomplished. 
Parameter 
Mobile Phase: 
Gradient: 
Flow Rate: 
Injection Volume: 
Column: 
Column Temperature: 
Detector Gas: 
Nebulizer Pressure: 
Capillary Voltage: 
MS 1 Resolution: 
MS2 Resolution: 
Run Time: 
Post Time: 
Table I. Instrument parameters 
Conditions 
A= 0.1 % formic acid in deionized water 
B = 0.1 % formic acid in acetonitri le 
Time 
0.0 
1.0 
5.0 
5.5 
0.5 mL/minute 
20 µL 
%A 
90 
90 
60 
10 
%B 
10 
10 
40 
90 
Agilent Rapid Resolution HT Zorbax SB-C3, 100 mm x 
3.0 mm i.d., 1.8 µm 
80 °C 
Nitrogen; 350 °C; 12.0 L/minute 
40 psi 
4000 y 
Wide 
Unit 
10 minutes 
3 minutes 
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Table II. Multiple reaction monitoring transitions 
Compound Transition Dwell (ms) Fragmentor Collision 
(v) Energy (v) 
GnRH 672.0 ---+ 908.3 75 132 24 
672.0 ---+ 249.1 75 132 32 
Peptide-I 515.4---+ 595.3 75 122 22 
515.4---+ 249.0 75 122 20 
Additional problems were encountered while selecting the final extraction 
solution. The conjugated protein proved to be difficult to cleave with clostripain. 
Various buffers were used in an attempt to maximize the recovery of Peptide-! 
from the GonaCon conjugate. It was hypothesized that the protein could be 
present in a folded conformation which might hinder the ability of the clostripain 
to cleave it. The use of 2,2,2-trifluoroethanol provided a minor denaturing effect 
which permitted the clostripain to cleave the GnRH. The enzyme system was 
optimized by investigation of the concentration of 2,2,2-trifluoroethanol which 
would permit the clostripain to still function while denaturing the conjugated 
GonaCon. A solution of 5% was found to be optimal. The time needed for the 
clostripain to cleave all of the GnRH present was also optimized. A reaction time 
of two hours was found to be sufficient for greater than 99% cleavage. 
Table III. Analytical recoveries of free and total GnRH in sham vaccine 
quality control samples (n=7) 
Fortification Level Range(%) Mean {°/o) Std. Dev. (%) CV(%) 
(µgig) 
Free GnRH 
150 91.3 - 103 99.3 4.1 4.1 
450 94.5 - 101 98.2 2.3 2.3 
Total GnRH 
150 106 - 127 116 11 9.5 
450 110 - 124 117 6.2 5.3 
Quality Control Results 
Mean recoveries of free and total GnRH in sham vaccine (n=7) quality control 
samples were excellent (Table Ill). 
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Method Limit of Detection 
The method limit of detection (MLOD) was estimated from the mean 
chromatographic response at the retention time of the parent (GnRH) or product 
(Peptide-I) peptide plus three times the response standard deviation from seven 
replicate control samples. The mean and standard deviation for GnRH was 
measured and found to be 3.881±0.335 ng/mL. The mean and standard deviation 
for Peptide- I was measured and found to be 1.577±0.458 ng/mL. Using these 
values, the MLOD for GnRH was estimated to be 2.1 µgig and the MLOD for 
Peptide-I was 1.6 µg/g. 
GnRH Determination in GonaCon Vaccine 
Six replicate samples of a formulated GonaCon vaccine with a target content 
of 300 µg/g were analyzed by the procedures outlined above. The range of 
observed values was 151 to 199 µg/g. The mean and standard deviation were 178 
µg/g and 18 µg/g respectively. 
Conclusion 
A highly selective and sensitive method for the determination of GnRH in 
GonaCon vaccines has been detailed. The method is repeatable and accurate. Use 
of this method will permit further investigation of the manufacturing and storage 
stability of this important wildlife management tool. 
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